erbitux® (cetuximab, reference drug  (CinnaGen Co)

Journal: Journal of Biomedical Optics

Article Title: Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models

doi: 10.1117/1.JBO.30.12.126002

Figure Lengend Snippet: Schematic overview of the experimental design and animal grouping. Female BALB/c nude mice bearing LS174T, SW948, or EGFR-high patient-derived xenograft (PDX) tumors were randomized into two groups ( n = 5 per group) receiving cetuximab-IRDye800CW ( 200 μ g ) or IgG-IRDye800CW ( 200 μ g ) via tail vein injection. Fluorescence imaging was performed daily from day 1 to 10 using open-field (LUNA) and closed-field (Pearl Impulse) systems under 775-nm excitation and 795-nm emission. Tumor-to-background ratio (TBR) and mean fluorescence intensity (MFI) were quantified, followed by ex vivo imaging and EGFR validation (Western blot, RT-qPCR, IHC).

Article Snippet: Cetuximab (MCE, Monmouth Junction, New Jersey, United States), a chimeric monoclonal antibody targeting the EGFR, was conjugated with the near-infrared fluorescent dye IRDye800CW (IRDye800CW-N-hydroxysuccinimide ester, LI-COR Biosciences, Lincoln, Nebraska, United States) under defined reaction conditions.

Techniques: Derivative Assay, Injection, Fluorescence, Imaging, Ex Vivo, Biomarker Discovery, Western Blot, Quantitative RT-PCR

Journal: Journal of Biomedical Optics

Article Title: Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models

doi: 10.1117/1.JBO.30.12.126002

Figure Lengend Snippet: Quantitative analysis of fluorescence imaging in SW948 and LS174T xenograft models [(a)–(c): SW948; (d)–(f): LS174T]. (a) Tumor-to-background ratio (TBR) curves of cetuximab-IRDye800CW and IgG-IRDye800CW groups in SW948 xenografts. The TBR in the cetuximab-IRDye800CW group progressively increased over time, reaching a peak of 21.6 ± 1.71 on day 10. (b) Comparison of mean fluorescence intensity (MFI) between tumor and background regions in SW948 xenografts. Tumor MFI in the cetuximab-IRDye800CW group remained consistently higher than background MFI throughout the imaging period. (c) Temporal changes in background MFI in SW948 xenografts, showing a marked decrease from 0.33 on day 1 to 0.15 on day 10 ( p < 0.05 ), indicating progressive clearance of nonspecific signals. (d) TBR curves of LS174T xenografts showing a similar trend, with significantly higher TBR values in the cetuximab-IRDye800CW group than in the IgG-IRDye800CW group at all time points, peaking at 25.6 ± 2.94 on day 10 ( p < 0.05 ). (e) Comparison of tumor and background MFI in LS174T xenografts. The cetuximab-IRDye800CW group exhibited stable and strong tumor-specific fluorescence, whereas no significant changes were observed in the control group. (f) Background MFI dynamics in LS174T xenografts, showing a gradual decline from 0.40 on day 1 to 0.05 on day 10 ( p < 0.05 ).

Article Snippet: Cetuximab (MCE, Monmouth Junction, New Jersey, United States), a chimeric monoclonal antibody targeting the EGFR, was conjugated with the near-infrared fluorescent dye IRDye800CW (IRDye800CW-N-hydroxysuccinimide ester, LI-COR Biosciences, Lincoln, Nebraska, United States) under defined reaction conditions.

Techniques: Fluorescence, Imaging, Comparison, Control

Journal: Journal of Biomedical Optics

Article Title: Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models

doi: 10.1117/1.JBO.30.12.126002

Figure Lengend Snippet: Open- and closed-field fluorescence imaging of SW948 and LS174T xenograft models. (a) Open-field images of SW948 xenografts showing visible tumor fluorescence in the cetuximab-IRDye800CW group from day 1, which intensified by day 10; IgG controls showed only weak background signals. (b) Closed-field images of SW948 xenografts confirming strong, tumor-localized fluorescence in the cetuximab-IRDye800CW group. (c) Open-field images of LS174T xenografts showing progressive tumor-specific fluorescence enhancement in the cetuximab-IRDye800CW group with minimal signal in controls. (d) Closed-field images of LS174T xenografts demonstrating clear, high-contrast fluorescence at tumor sites in the cetuximab-IRDye800CW group compared with negligible background in controls. These results confirm selective, strong, and progressively enhanced tumor-targeted fluorescence with cetuximab-IRDye800CW in both models.

Article Snippet: Cetuximab (MCE, Monmouth Junction, New Jersey, United States), a chimeric monoclonal antibody targeting the EGFR, was conjugated with the near-infrared fluorescent dye IRDye800CW (IRDye800CW-N-hydroxysuccinimide ester, LI-COR Biosciences, Lincoln, Nebraska, United States) under defined reaction conditions.

Techniques: Fluorescence, Imaging

Journal: Journal of Biomedical Optics

Article Title: Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models

doi: 10.1117/1.JBO.30.12.126002

Figure Lengend Snippet: Fluorescence imaging of EGFR-high patient-derived xenograft (PDX) models. (a) Representative fluorescence images on day 1 showing clear tumor-specific signals in the cetuximab-IRDye800CW group, whereas the IgG-IRDye800CW control group exhibited negligible background fluorescence. (b) Fluorescence images on day 10, demonstrating markedly enhanced tumor-localized fluorescence in the cetuximab-IRDye800CW group with no detectable tumor signal in controls. These results confirm stable and progressively increased tumor-targeted fluorescence in the PDX model following cetuximab-IRDye800CW administration.

Article Snippet: Cetuximab (MCE, Monmouth Junction, New Jersey, United States), a chimeric monoclonal antibody targeting the EGFR, was conjugated with the near-infrared fluorescent dye IRDye800CW (IRDye800CW-N-hydroxysuccinimide ester, LI-COR Biosciences, Lincoln, Nebraska, United States) under defined reaction conditions.

Techniques: Fluorescence, Imaging, Derivative Assay, Control

Journal: Journal of Biomedical Optics

Article Title: Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models

doi: 10.1117/1.JBO.30.12.126002

Figure Lengend Snippet: EGFR expression and tumor fluorescence across models. (a) Western blot analysis of EGFR in LS174T and SW948 cell lines. (b) Bar graph depicting EGFR protein levels (densitometry) in LS174T and SW948. (c) Bar graph showing EGFR mRNA expression in LS174T and SW948 (RT-qPCR). (d) H&E staining and EGFR immunohistochemistry of tumors in LS174T, SW948, and PDX models after euthanasia, showing strong membrane EGFR expression. (e) Tumor-to-background ratio (TBR) comparison demonstrating significantly higher values in cetuximab-IRDye800CW-treated mice compared with IgG controls across all three models.

Article Snippet: Cetuximab (MCE, Monmouth Junction, New Jersey, United States), a chimeric monoclonal antibody targeting the EGFR, was conjugated with the near-infrared fluorescent dye IRDye800CW (IRDye800CW-N-hydroxysuccinimide ester, LI-COR Biosciences, Lincoln, Nebraska, United States) under defined reaction conditions.

Techniques: Expressing, Fluorescence, Western Blot, Quantitative RT-PCR, Staining, Immunohistochemistry, Membrane, Comparison